度普利尤单抗治疗慢性鼻窦炎伴鼻息肉的不良反应:真实世界单机构经验
该回顾性队列研究纳入2020至2023年在一家三级医疗机构接受度普利尤单抗治疗慢性鼻窦炎伴鼻息肉的115例患者,随访至少6个月。39例报告至少1种不良反应,15例(13.0%)因不良反应停药,眼部不良反应最常见(15例)。女性与发生不良反应及因不良反应停药显著相关。
要点
- 115例中39例报告至少1种不良反应,15例(13.0%)因不良反应停药。
- 眼部不良反应最常见(15例),其次为注射部位反应(10例)、肌肉骨骼(9例)和非注射部位皮肤反应(8例)。
- 女性与发生不良反应及因不良反应停药显著相关。
核心结论
- 度普利尤单抗是控制不佳的慢性鼻窦炎伴鼻息肉的有效治疗选择,但不良反应发生率和停药率高于III期试验报告。
- 更多真实世界不良反应数据有助于临床决策和患者咨询。
研究设计与样本
- 回顾性队列研究,在单家三级医疗机构开展。
- 纳入2020至2023年四年期间因慢性鼻窦炎伴鼻息肉开始度普利尤单抗治疗且随访至少6个月的患者。
- 采用单因素分析和多因素logistic回归分析与不良反应相关的临床因素,单因素分析用于确定因不良反应停药的相关因素。
主要发现
- 115例患者至少接受一剂度普利尤单抗,平均年龄(标准差)为51.0(14.9)岁,44%为女性。
- 39例报告至少1种不良反应,其中15例有超过1种不良反应;15例(13.0%)因不良反应停药。
- 眼部不良反应最常见(15例),其次为注射部位反应(10例)、肌肉骨骼(9例)和非注射部位皮肤反应(8例)。
- 女性与发生不良反应及因不良反应停药显著相关。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Phase III trials have shown that dupilumab is an effective and well-tolerated adjunct treatment for patients with uncontrolled chronic rhinosinusitis with nasal polyps (CRSwNP). However, real-world data pertaining to tolerability and adverse effects (AE) are lacking. The goal of this study is to investigate AE incidence, timing, and medication discontinuation. METHODS: This is a retrospective cohort study at a single tertiary care institution. Patients initiating treatment with dupilumab for CRSwNP over a four-year period (2020-2023) with at least six months of follow-up were included. Univariate analysis and multivariable logistic regression were performed to investigate relevant clinical factors associated with AEs. Univariate analysis was also performed to determine factors associated with discontinuation due to AEs. RESULTS: 115 patients received at least one dose of dupilumab. Mean age (SD) was 51.0 (14.9) years, and 44% were female. 39 patients reported at least one AE, with 15 having more than one AE. 15 patients (13.0%) discontinued the medication due to an AE. Ocular AEs were the most common (15), followed by injection site reactions (10), musculoskeletal (9), and non-injection site skin reactions (8). Female sex was significantly associated with AEs and discontinuation due to AEs. CONCLUSION: While dupilumab is an effective treatment option for uncontrolled CRSwNP, the incidence of AEs and discontinuation rates were higher than reported in Phase III trials. Additional real-world data pertaining to AEs can aid in clinical decision-making and patient counseling.
引用
- Wang AJ, Jiang R, Runyan T, et al. Adverse Effects of Dupilumab for Chronic Rhinosinusitis With Nasal Polyposis: Real-World Single Institution Experience. Laryngoscope. 2025. PMID: 40525458. doi:10.1002/lary.32359
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。